Oslo, Norway, 27 August 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that the abstract "A pilot study of Engineered
Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint
inhibitor refractory advanced or unresectable melanoma" will be presented as an
e-poster at the European Society for Medical Oncology (ESMO) congress by Dr
Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.

E-poster    A pilot study of Engineered Adenovirus ONCOS-102 in combination
title:      with pembrolizumab (pembro) in checkpoint inhibitor refractory
            advanced or unresectable melanoma
E-poster    1083P
number:
Presenter:  Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center

The abstract will be released on the ESMO website 13 September 00:05 CEST
(https://www.esmo.org/meetings/esmo-congress-2021). The results from the
completed phase 1 trial will be presented during the ESMO congress 16-21
September 2021.



About ESMO

ESMO is the leading professional organisation for medical oncology. With more
than 23,000 members representing oncology professionals from over 150 countries
worldwide, ESMO is the society of reference for oncology education and
information. ESMO is committed to offer the best care to people with cancer,
through fostering integrated cancer care, supporting oncologists in their
professional development, and advocating for sustainable cancer care worldwide.

***

For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company's product candidates are designed to harness the
patient's own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.